Evotec SE

EVT: XETR (DEU)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
€2.60KzxyKsyzblqd

Evotec Earnings: Navigating Market Challenges With a Focus on Achieving Long-Term Profitability

No-moat Evotec is facing a challenging environment due to the slowdown in early-stage research and development spending. While total revenue rose 2% year over year in the first half of 2024, primarily driven by strong performance in the Just-Evotec Biologics segment, this top-line growth was partly offset by ongoing difficulties in the shared R&D segment, which struggled with stagnant spending by biotechnology clients. We keep our fair value estimates of EUR 8.50 and $4.63 per share. Shares currently trade about 30% below our fair value estimate.

Sponsor Center